In the latest trading session, 17.83 million Vincerx Pharma Inc (NASDAQ:VINC) shares changed hands as the company’s beta touched 1.24. With the company’s most recent per share price at $1.00 changing hands around $0.17 or 20.39% at last look, the market valuation stands at $2.24M. VINC’s current price is a discount, trading about -15080.0% off its 52-week high of $151.80. The share price had its 52-week low at $0.75, which suggests the last value was 25.0% up since then. When we look at Vincerx Pharma Inc’s average trading volume, we note the 10-day average is 87390.0 shares, with the 3-month average coming to 884.35K.
Analysts gave the Vincerx Pharma Inc (VINC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VINC as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Vincerx Pharma Inc’s EPS for the current quarter is expected to be 0.
Vincerx Pharma Inc (NASDAQ:VINC) trade information
Instantly VINC is in green as seen in intraday trades today. With action 21.83%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -81.01%, with the 5-day performance at 21.83% in the green. However, in the 30-day time frame, Vincerx Pharma Inc (NASDAQ:VINC) is -23.23% down. Looking at the short shares, we see there were 0.19 million shares sold at short interest cover period of 0.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 50.0% from its recent market value. According to analyst projections, VINC’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -100.0% plunge from its current level, while the stock would need to soar -100.0% for it to hit the projected low.
Vincerx Pharma Inc (VINC) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -284.14%. The 2025 estimates are for Vincerx Pharma Inc earnings to increase by 59.79%.
Vincerx Pharma Inc (NASDAQ:VINC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.59% of Vincerx Pharma Inc shares while 10.77% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 12.18%. There are 10.77% institutions holding the Vincerx Pharma Inc stock share, with GOLDMAN SACHS GROUP INC the top institutional holder. As of 2024-06-30, the company held 2.9506% of the shares, roughly 0.63 million VINC shares worth $0.51 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 2.932% or 0.63 million shares worth $0.51 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. With 14.02 shares estimated at $11414.0 under it, the former controlled 0.03% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.02% of the shares, roughly 7.18 shares worth around $5849.0.
